DLL3
- 产品详情
- 实验流程
Primary Accession | Q9NYJ7-1 |
---|---|
Species | Human |
Sequence | Val311-Ala479 |
Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
Endotoxin Level | Less than 1EU per µg by the LAL method. |
Biological Activity | Immobilized DLL3 Domain (311-479), His&Avi, Human (Cat.No.: Z03951) at 1 µg/ml (100 µl/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag |
Expression System | HEK293 |
Theoretical Molecular Weight | 21.20 kDa |
Formulation | Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4). |
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 µg/ml. |
Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background | Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors. |
---|
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.